Skip to main content

Table 4 Most frequently (≥3% of patients) reported adverse events

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

System Organ Class
Preferred Term, n (%)
NGX-4010
(n = 102)
Control
(n = 53)
Number of Patients Reporting 1 or More Adverse Events 76 (75%) 28 (53%)
Gastrointestinal Disorders 10 (10%) 4 (8%)
   Nausea 5 (5%) 1 (2%)
General Disorders and Administration Site Conditions 38 (37%) 12 (23%)
   Application Site Burning 3 (3%) 0
   Application Site Discoloration 0 3 (6%)
   Application Site Dryness 10 (10%) 2 (4%)
   Application Site Erythema 4 (4%) 0
   Application Site Pain 4 (4%) 2 (4%)
   Application Site Papules 4 (4%) 2 (4%)
   Application Site Pruritus 17 (17%) 6 (11%)
   Application Site Swelling 10 (10%) 1 (2%)
   Application Site Urticaria 3 (3%) 0
   Application Site Vesicles 5 (5%) 1 (2%)
   Pain Exacerbated 3 (3%) 0
Infections and Infestations 16 (16%) 8 (15%)
   Bronchitis 3 (3%) 0
   Herpes Zoster 3 (3%) 2 (4%)
   Upper Respiratory Tract Infection 1 (1%) 2 (4%)
Injury, Poisoning and Procedural Complications 4 (4%) 6 (11%)
   Injury 1 (1%) 2 (4%)
Musculoskeletal and Connective Tissue Disorders 10 (10%) 2 (4%)
   Back Pain 3 (3%) 1 (2%)
Nervous Systems Disorders 5 (5%) 5 (9%)
   Dizziness 1 (1%) 3 (6%)
Respiratory, Thoracic and Mediastinal Disorders 12 (12%) 4 (8%)
   Cough 3 (3%) 0
   Nasal Congestion 1 (1%) 2 (4%)
   Nasopharyngitis 3 (3%) 2 (4%)
Vascular Disorders 5 (5%) 1 (2%)
   Hypertension 3 (3%) 0